Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Sales and Divestitures: 2016-2025

Historic Gains from Sales and Divestitures for Theravance Biopharma (TBPH) over the last 2 years, with Sep 2025 value amounting to $336,744.

  • Theravance Biopharma's Gains from Sales and Divestitures rose 13.27% to $336,744 in Q3 2025 from the same period last year, while for Sep 2025 it was $336,744, marking a year-over-year increase of 13.27%. This contributed to the annual value of $1.6 million for FY2024, which is 0.64% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Gains from Sales and Divestitures is $336,744, which was down 18.51% from $413,240 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Gains from Sales and Divestitures peaked at $3.8 million during Q4 2022, and registered a low of $297,284 during Q3 2024.
  • In the last 3 years, Theravance Biopharma's Gains from Sales and Divestitures had a median value of $413,240 in 2025 and averaged $759,286.
  • Per our database at Business Quant, Theravance Biopharma's Gains from Sales and Divestitures surged by 40.63% in 2021 and then slumped by 56.17% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Gains from Sales and Divestitures stood at $2.7 million in 2021, then skyrocketed by 40.44% to $3.8 million in 2022, then plummeted by 56.17% to $1.7 million in 2023, then fell by 0.64% to $1.6 million in 2024, then climbed by 13.27% to $336,744 in 2025.
  • Its Gains from Sales and Divestitures stands at $336,744 for Q3 2025, versus $413,240 for Q2 2025 and $619,026 for Q1 2025.